Earnings Releases·Nov 10, 2026, 7:35 AM ET

Xilio Therapeutics — Third Quarter 2026 Earnings Summary

Net loss narrowed to $5.9 million (EPS: $(0.30)) from $16.3 million (EPS: $(1.58)) in Q3 2025, driven by a $4.8 million gain on warrant liability fair value changes; collaboration revenue declined 48% to $10.0 million from $19.1 million year-over-year.
Cash and cash equivalents decreased to $122.2 million from $137.5 million at year-end 2025, though total liabilities fell significantly to $66.6 million from $119.4 million, with equity rising to $68.2 million.
Management anticipates existing cash will fund operations through Q1 2028 and targets initial Phase 1 data for XTX501 in Q4 2027, alongside IND submissions for XTX602 and XTX701 in the same period.
Potential near-term capital includes up to $36.2 million from Series C warrant exercises in Q4 2026 and up to $31.0 million in milestone/option fees from the AbbVie collaboration through H1 2027.
Strategic pipeline progress includes dosing the first patient in the XTX501 Phase 1 trial, advancing XTX602 and XTX701 toward IND filings, and appointing Yariv Houvras as Chief Medical Officer in September 2026.